Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) EPS (Basic): 2009-2025

Historic EPS (Basic) for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $7.73.

  • UNITED THERAPEUTICS's EPS (Basic) rose 11.54% to $7.73 in Q3 2025 from the same period last year, while for Sep 2025 it was $28.48, marking a year-over-year increase of 17.15%. This contributed to the annual value of $26.44 for FY2024, which is 25.67% up from last year.
  • Per UNITED THERAPEUTICS's latest filing, its EPS (Basic) stood at $7.73 for Q3 2025, which was up 12.68% from $6.86 recorded in Q2 2025.
  • UNITED THERAPEUTICS's EPS (Basic)'s 5-year high stood at $7.73 during Q3 2025, with a 5-year trough of $0.63 in Q1 2021.
  • For the 3-year period, UNITED THERAPEUTICS's EPS (Basic) averaged around $6.29, with its median value being $6.52 (2024).
  • Its EPS (Basic) has fluctuated over the past 5 years, first plummeted by 79.94% in 2021, then spiked by 742.86% in 2022.
  • UNITED THERAPEUTICS's EPS (Basic) (Quarterly) stood at $2.48 in 2021, then grew by 14.52% to $2.84 in 2022, then spiked by 61.97% to $4.60 in 2023, then surged by 45.87% to $6.71 in 2024, then grew by 11.54% to $7.73 in 2025.
  • Its EPS (Basic) stands at $7.73 for Q3 2025, versus $6.86 for Q2 2025 and $7.18 for Q1 2025.